Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Study findings support the monitoring and management of iron status in patients with early stages of chronic kidney disease (CKD).

AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.

Akebia Therapeutics, Inc.’s AKBA share price has dipped by 28.17%, which has investors questioning if this is right time to ...

Your kidneys are the heroes of your body, silently working around the clock to filter out waste, regulate fluids, and ...

Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Akebia Therapeutics faces a 28% stock drop amid financial woes, declining revenues, and competitive challenges. Read more on ...

Discover the telltale symptoms of iron deficiency anemia and learn strategies to restore your energy, from dietary changes to ...

Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of FibroGen in a report released on Tuesday, March 18th. HC Wainwright analyst M. Keller expects that the ...